United States (US)

BMF peptide

Cat No. GTX29654

Application Blocking
Species Human

Application Note

The peptide is used for blocking the activity of anit-Bmf (C terminal) antibody (GTX29654). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theactivity of anti-Bmf (C terminal) in Western blotting.




PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide


Store the peptide at -20˚C, stable for one year.


0.20 mg/ml (Please refer to the vial label for the specific concentration.)




For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


Bcl2 Modifying Factor,Bmf


Apoptosis is related to many diseases and development. Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3-only proteins, including Bad, Bid, Bik, Hrk, Bim, Noxa, and PUMA, form a growing subclass of the Bcl-2 family. A novel BH3-only protein was recently identified in human and mouse and designated Bmf (for Bcl-2-modifing factor) (1). The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cell's actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program (1,2). Bmf is constitutively expressed in many tissues (1,2).

Research Area

Package List Price ($)
$ 179